The Clinical Trial of ADR-001 for IgA Nephropathy
- Conditions
- Glomerulonephritis, IGAProteinuria, HematuriaD005922
- Registration Number
- JPRN-jRCT2043200002
- Lead Sponsor
- Maruyama Shoichi
- Brief Summary
When ADR-001 was administered once or twice to patients with IgA nephropathy resistant to existing therapies, safety was confirmed and symptoms were partially improved.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 9
1) IgA nephropathy diagnosed by renal biopsy.
2) Meet any of the following criteria.
i. Urinary protein at screening is 0.5 g / gCr or more and eGFR is 60 mL / min / 1.73m^2 or more even if corticosteroids are used for 6 months or more before screening.
ii. Urine protein of 1.0 g / gCr or more and eGFR of 30 mL / min / 1.73 m^2 or more and less than 60 mL / min / 1.73 m^2 at screening even if corticosteroids are used for 6 months or more before screening.
iii. Urine protein of 0.5 g / gCr or more and less than 1.0 g / gCr at screening and eGFR of 20 mL / min / 1.73m^2 or more and 60 mL / min / 1.73m^2 or urine protein of 1.0 g / gCr or more at screening And eGFR is 20 mL / min / 1.73m^2 or more and less than 30 mL / min / 1.73m^2.
3) Over 20 years old.
4) Able to provide informed consent.
However, in the first cohort, only 2) -i is applied in the selection criteria 2), and in the second cohort, 2) -i, ii, and iii are applied.
1) Nephropathy other than IgA nephropathy, and primary and secondary nephrotic syndrome.
2) Start or increase drug therapy for IgA nephropathy with corticosteroids, immunosuppressants, renin angiotensin system (RAS ) inhibitors, antiplatelet drugs, anticoagulants (warfarin), and n-3 fatty acids (fish oil) within 3 months . Palatal tonsillectomy within 6 months.
3) Treatment with other cells.
4) Participated within 3 months or participating in other clinical trials .
5) Penal transplantation within 3 years or scheduled.
6) Diabetics not well controlled.
7) Malignant neoplasm or history of malignant neoplasm within 5 years, or judged possibility of malignant tumor.
8) Suspected of active infection.
9) Positive for hepatitis B (HB), hepatitis C virus (HCV),human Immunodeficiency virus (HIV), human T-cell leukemia virus 1 (HTLV-1) or syphilis.
10) History of severe hypersensitivity or anaphylactic reaction.
11) Allergic to penicillin antibiotics, aminoglycoside antibiotics or dimethyl sulfoxide (DMSO).
12) Serious complications not related to IgA nephropathy.
13) Bleeding or may bleed, shallow days after surgery or trauma to the central nervous system, history of hypersensitivity to components of heparin preparations, history of heparin-induced thrombocytopenia Previous patient.
14) During pregnancy, lactation, may be pregnant or both men and women who do not agree to give birth control under the guidance of the investigator or investigator during the study period.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method